
    
      The study team chose a treatment protocol with NR as a treatment for patients who will be
      admitted with COVID-19 related illness and develop AKI after admission. Treatment duration
      will be for 10 days and the primary study endpoint will be the change in whole blood NAD+
      from baseline to end of treatment in NR group vs placebo group. The study team will evaluate
      whole blood NAD+ levels as a marker of efficacy and biological effect of NR.
    
  